Lynne E. Wagoner
Medical Practice in Cincinnati, OH
License number
Kentucky 33837
Issued Date
Mar 19, 1998
Expiration Date
Feb 28, 2007
Category
Cardiovascular Disease
Type
Faculty
Address
Address
231 Albert Sabin Way, Ml 0542, Cincinnati, OH 45267
Education
The Brody School of Medicine at East Carolina University, Greenville, 1986
Phone
(513) 558-3487 (Work)
Personal information
See more information about Lynne E. Wagoner at radaris.comName
Address
Phone
3003 Observatory Ave, Cincinnati, OH 45208
231 Bethesda Ave, Cincinnati, OH 45229
3003 Observatory Ave, Cincinnati, OH 45208
2123 Auburn Ave, Cincinnati, OH 45219
234 Goodman St, Cincinnati, OH 45219
Professional information
Dr. Lynne E Wagoner, West Chester OH - MD (Doctor of Medicine)
Specialties:
Cardiology, Advanced Heart Failure & Transplant Cardiology
Address:
UNIVERSITY POINTE INTMED & PEDIATRICS
7690 Discovery Dr SUITE 2700, West Chester 45069
(513) 475-7425 (Phone), (513) 475-7453 (Fax)
Mercy Heart Institute
4030 Smith Rd SUITE 350, Cincinnati 45209
(513) 751-4222 (Phone)
Mercy Heart Institute
3000 Mack Rd SUITE 100, Fairfield 45014
(513) 751-4222 (Phone)
7690 Discovery Dr SUITE 2700, West Chester 45069
(513) 475-7425 (Phone), (513) 475-7453 (Fax)
Mercy Heart Institute
4030 Smith Rd SUITE 350, Cincinnati 45209
(513) 751-4222 (Phone)
Mercy Heart Institute
3000 Mack Rd SUITE 100, Fairfield 45014
(513) 751-4222 (Phone)
Procedures:
Cardiac Catheterization (incl. Coronary Angiography), Cardiac Imaging, Chest CT (incl. Heart and Lungs), Coronary Angioplasty, Atherectomy and Stent
Conditions:
Aneurysm and Dissection of Heart, Autonomic Disorders, Carotid Artery Disease, Endocarditis, Heart Attack (Acute Myocardial Infarction), Hyperlipidemia, Hypertension, Hypertensive Heart and Chronic Kidney Disease, Hypertensive Heart Disease, Hypotension, Lipidoses (incl. Gaucher Disease), Marfan Syndrome, Pericardial Disease, Pulmonary Hypertension, Pulmonary Valve Disease, Syncope, Tricuspid Valve Disease
Certifications:
Advanced Heart Failure and Transplant Cardiology, 2012, Cardiovascular Disease, 2003, Internal Medicine, 1989
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
UNIVERSITY POINTE INTMED & PEDIATRICS
7690 Discovery Dr SUITE 2700, West Chester 45069
Mercy Heart Institute
4030 Smith Rd SUITE 350, Cincinnati 45209
Mercy Heart Institute
3000 Mack Rd SUITE 100, Fairfield 45014
Fort Hamilton Hughes Memorial Hospital
630 Eaton Ave, Hamilton 45013
Mercy Health - Fairfield Hospital
3000 Mack Rd, Fairfield 45014
Mercy Health - Anderson Hospital
7500 State Rd, Cincinnati 45255
7690 Discovery Dr SUITE 2700, West Chester 45069
Mercy Heart Institute
4030 Smith Rd SUITE 350, Cincinnati 45209
Mercy Heart Institute
3000 Mack Rd SUITE 100, Fairfield 45014
Fort Hamilton Hughes Memorial Hospital
630 Eaton Ave, Hamilton 45013
Mercy Health - Fairfield Hospital
3000 Mack Rd, Fairfield 45014
Mercy Health - Anderson Hospital
7500 State Rd, Cincinnati 45255
Education:
Medical School
East Carolina University / Brody School of Medicine
Graduated: 1986
Pitt Co Meml Hosp-E Carolina U
University Of Utah
East Carolina University / Brody School of Medicine
Graduated: 1986
Pitt Co Meml Hosp-E Carolina U
University Of Utah
Methods For Diagnosis, Prediction And Treatment Of Heart Failure And Other Cardiac Conditions Based On Beta1-Adrenergic Receptor Polymorphism
US Patent:
2005011, May 26, 2005
Filed:
Sep 13, 2004
Appl. No.:
10/941063
Inventors:
Stephen Liggett - Cincinnati OH, US
Lynne Wagoner - Cincinnati OH, US
Lynne Wagoner - Cincinnati OH, US
International Classification:
C12Q001/68, C12P019/34
US Classification:
435006000, 435091200
Abstract:
Methods and compositions for the detection, diagnosis, and prevention of cardiac conditions are provided. Polymorphisms of β-adrenergic receptor are provided. The Gly389 β-adrenergic receptor variants are not as responsive to treatment β blockers such as carvedilol, metoprolol or bisoprol. Thus, genotyping β-adrenergic receptor polymorphisms is useful for predicting relative responsiveness to treatment with beta blockers. The Gly389 polymorphism also may be used, alone or in conjunction with other adrenergic receptor polymorphisms, to predict relative risk of developing cardiovascular diseases such as heart failure or to predict relative survival rate in patients with heart failure or other cardiovascular diseases. Also provided are transgenic mice and transgenic cells expressing the β-adrenergic receptor polymorphisms, and their use in identifying therapeutic agents.